8-K: Liminatus Pharma Executes 1-for-50 Reverse Stock Split to Maintain Nasdaq Listing

Liminatus Pharma announced a 1-for-50 reverse stock split, effective August 20, 2026, to regain compliance with Nasdaq listing requirements.

Summary

• Liminatus Pharma, Inc. has filed a Form 8-K detailing actions taken to maintain its listing on The Nasdaq Stock Market.
• The company received multiple notices from Nasdaq regarding non-compliance with continued listing requirements, including minimum Market Value of Listed Securities (MVLS), Market Value of Publicly Held Shares (MVPHS), and minimum bid price.
• To address these deficiencies, the company's board of directors approved a 1-for-50 reverse stock split of its common stock.
• This reverse stock split is intended to increase the stock's bid price to meet Nasdaq's minimum requirement of $1.00 per share.
• The reverse stock split will be effective at the close of trading on August 20, 2026, with trading on a split-adjusted basis expected to begin on August 21, 2026.
• The company has been granted an exception by the Nasdaq Hearings Panel to regain compliance with listing rules, with a deadline of September 3, 2026, to demonstrate a $1.00 closing bid price for at least ten consecutive trading days.
• Fractional shares resulting from the split will be rounded up to the nearest whole share, with no cash consideration paid.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the company is undertaking a reverse stock split primarily to avoid delisting, indicating underlying financial and market value struggles.

Positives

• The company has successfully negotiated an exception and a brief extension from the Nasdaq Hearings Panel to regain compliance with listing rules.
• The reverse stock split is expected to bring the stock price above the $1.00 minimum bid price requirement.
• The company has regained compliance with the stockholders equity rule and the MVPHS requirement as part of the phase-down to The Nasdaq Capital Market.
• Fractional shares will be rounded up to the nearest whole share, which is a favorable outcome for affected shareholders.

Negatives

• The company was previously non-compliant with Nasdaq's MVLS, MVPHS, and Bid Price Rules.
• The need for a reverse stock split indicates a significant decline in the company's market value and stock price.
• There is no assurance that the company will be able to regain compliance with the listing rules within the prescribed time period.
• The reverse stock split does not fundamentally change the company's business or financial performance, but rather addresses a technical listing requirement.

Risks

• Failure to demonstrate compliance with Listing Rule 5550(a)(2) by September 3, 2026, could result in delisting from The Nasdaq Capital Market.
• The company's ability to implement its business plans may be affected by ongoing financial and market conditions.
• The highly competitive biotechnology industry presents risks from new entrants and a changing regulatory landscape.
• Forward-looking statements are subject to uncertainties that could cause actual results to differ materially from expectations.

Future Outlook

The company expects that following the effectiveness of the Reverse Stock Split, it will regain compliance with Listing Rule 5550(a)(2) (minimum $1.00 bid price for ten consecutive trading days). However, there can be no assurance that this will occur within the prescribed time period.

Management Comments

• The Board of Directors approved a 1-for-50 reverse stock split to meet the minimum bid price and other quantitative requirements for Nasdaq listing.
• The Company expects that following the effectiveness of the Reverse Stock Split, the Company will regain compliance with Listing Rule 5550(a)(2); however, there can be no assurance that the Company will be able to regain compliance within the prescribed time period.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often negative, signal in the biotechnology sector when companies struggle to maintain minimum bid prices required for exchange listing. This often reflects challenges in clinical development, funding, or market perception.

Stakeholder Impact

• Shareholders will experience a significant reduction in their number of shares held, though their proportionate ownership interest is intended to remain unchanged.
• Holders of equity awards and warrants will see proportionate adjustments to their share counts and exercise/conversion prices.

Next Steps

• Demonstrate compliance with Listing Rule 5550(a)(2) by achieving a $1.00 closing bid price for at least ten (10) consecutive trading days on or before September 3, 2026.
• Common stock to begin trading on a split-adjusted basis on The Nasdaq Capital Market at market open on August 21, 2026.
• Stockholders holding paper certificates may send them to the transfer agent to receive new certificates reflecting the reverse stock split.

Key Dates

Recommendation

The reverse stock split is a necessary measure to maintain Nasdaq listing but does not address the underlying business challenges that led to the low stock price. While it prevents immediate delisting, it does not inherently improve the company's prospects. Investors should monitor the company's ability to achieve sustained compliance and progress in its drug development pipeline.

Keywords

reverse stock split, Nasdaq listing, compliance, bid price, biotechnology, delisting, capital market, stockholder equity